Lymph node metastasis in head and neck squamous cell carcinoma: risk stratification, diagnosis, and management
Abstract
PurposeTo establish a risk-stratified management framework for cervical lymph node metastasis (LNM) in head and neck squamous cell carcinoma (HNSCC) by integrating AJCC 9th edition staging, the 2024 HNCIG extranodal extension (ENE) consensus, AI radiomics, and modern immunotherapy, with critical appraisal of clinical utility and external validation.MethodsA PRISMA 2020-compliant systematic review of 49 high-quality studies identified through database search (January 2019–April 30, 2025), with 3 additional post-cutoff studies used for background context; stratified quality assessment was performed using RoB 2, NOS, AMSTAR 2, and QUADAS-2.FindingUnified pathological-radiological ENE criteria were consolidated for HNSCC; AI radiomics showed promising but insufficiently externally validated performance for occult metastasis prediction; risk-adapted algorithms integrating selective neck dissection, adjuvant anti–PD-1 immunotherapy, and de-escalation were constructed for specific risk strata.ConclusionThis review provides a risk-stratified evidence synthesis for LNM management in HNSCC, while highlighting that radiomics models require prospective multicenter validation before clinical deployment, and that management recommendations should be applied within appropriate risk and disease strata.
Related
- Zebrafish xenograft models as a fast platform for metastasis diagnosis and cisplatin response of head and neck squamous cell carcinoma
- Giant cutaneous squamous cell carcinoma in situ with progression to lymph node metastasis
- Combined apparent diffusion coefficient histogram and MRI-based fractal analysis for predicting lymph node metastasis in esophageal squamous cell carcinoma
- CT-to-surgery interval and occult nodal metastasis in cN0 oral squamous cell carcinoma
- Radiomics-based machine learning models decipher heterogeneity of anoikis-related molecular subtypes for prognostic stratification in head and neck squamous cell carcinoma
BibTeX
@article{you2026lymph,
title = {{Lymph node metastasis in head and neck squamous cell carcinoma: risk stratification, diagnosis, and management}},
author = {Jingmin You},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1999289},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1999289},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Lymph node metastasis in head and neck squamous cell carcinoma: risk stratification, diagnosis, and management
AU - Jingmin You
PY - 2026
DA - 2026/11/09
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1999289
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1999289
AB - PurposeTo establish a risk-stratified management framework for cervical lymph node metastasis (LNM) in head and neck squamous cell carcinoma (HNSCC) by integrating AJCC 9th edition staging, the 2024 HNCIG extranodal extension (ENE) consensus, AI radiomics, and modern immunotherapy, with critical appraisal of clinical utility and external validation.MethodsA PRISMA 2020-compliant systematic review of 49 high-quality studies identified through database search (January 2019–April 30, 2025), with 3 additional post-cutoff studies used for background context; stratified quality assessment was performed using RoB 2, NOS, AMSTAR 2, and QUADAS-2.FindingUnified pathological-radiological ENE criteria were consolidated for HNSCC; AI radiomics showed promising but insufficiently externally validated performance for occult metastasis prediction; risk-adapted algorithms integrating selective neck dissection, adjuvant anti–PD-1 immunotherapy, and de-escalation were constructed for specific risk strata.ConclusionThis review provides a risk-stratified evidence synthesis for LNM management in HNSCC, while highlighting that radiomics models require prospective multicenter validation before clinical deployment, and that management recommendations should be applied within appropriate risk and disease strata.
SN - 2234-943X
ER -